Gestational age at initiation of 17α-hydroxyprogesterone caproate (17P) and recurrent preterm delivery

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 20, Issue 3, 2007, Pages 249-252

  González Quintero, Víctor Hugo ^a   Istwan, Niki B ^b   Rhea, Debbie J ^b   Smarkusky, Loren ^a   Hoffman, M Camille ^a   Stanziano, Gary J ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b Matria Healthcare Inc   (United States)

Author keywords

17 hydroxyprogesterone caproate; Preterm birth prevention; Preterm delivery

Indexed keywords

HYDROXYPROGESTERONE CAPROATE; 17-ALPHA-HYDROXY-PROGESTERONE CAPROATE; PROGESTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FISHER EXACT TEST; GESTATIONAL AGE; HEALTH EDUCATION; HUMAN; MAJOR CLINICAL STUDY; NURSING ASSESSMENT; OUTPATIENT CARE; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; RANK SUM TEST; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; EVALUATION; PREGNANCY; PREMATURITY; RETROSPECTIVE STUDY; UTERINE CERVIX CERCLAGE;

ADULT; CERCLAGE, CERVICAL; FEMALE; GESTATIONAL AGE; HUMANS; HYDROXYPROGESTERONES; PREGNANCY; PREMATURE BIRTH; PROGESTERONE CONGENERS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 34347392550     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050601152845     Document Type: Article

References (15)

1. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologist. Number 43, May 2003. Management of preterm labor. Obstet Gynecol 2003;101:1039-1047.
2. Papiernik E. Double blind study of an agent to prevent preterm delivery among women at increased risk. Schering ed. Series IV 1970:65-68.
3. Johnson JW, Austin KL, Jones GS, Davis GH, King TM. Efficacy of 17α-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975;293:675-680.
4. Yemini M, Borenstein R, Dreazen E, Apelman Z, Mogilner BM, Kessler I, Lancet M. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 1985;151:574-577.
5. Hartikainen-Sorri A-L, Kauppila A, Tuimala R. Inefficacy of 17α hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol 1980;56:692-695.
6. Hauth JC, Gilstrap LC III, Brekken AL, Hauth JM. The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol 1983;146:187-190.
7. Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta-analysis of randomized controls trials of progestational agents in pregnancy. Br J Obstet Gynaecol 1989;96:265-274.
8. Meis PJ, Klevanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-2385.
9. Sanchez-Ramos L, Kaunitz AM, Delke I. Progestational agents to prevent preterm birth: A meta-analysis of randomized controlled trials. Obstet Gynecol 2005;105:273-279.
10. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 291. Use of progesterone to reduce preterm birth. Obstet Gynecol 2003;102:1115-1116.
11. Koontz G. Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17-OHCP) in preventing recurrent preterm delivery? Am J Obstet Gynecol 2005;193:S55.
12. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled double blind study. Am J Obstet Gynecol 2003;1884:419-424.
13. Iams JD, Goldenberg RL, Mercer BM, Moawad A, Thom E, Meis PJ, McNellis D, Caritis SN, Miodovnik M, Menard MK, et al. The preterm prediction study: Recurrence risk of spontaneous preterm birth. National Institute of Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1998;178:1035-1040.
14. Adams MM, Elam-Evans LD, Wilson HG, Gilberts DA. Rates of and factors associated with recurrence of preterm delivery. JAMA 2000;283:1591-1596.
15. Meis PJ, Klebanoff M, Dombrowski MP, Sibai BM, Leindecker S, Moawad AH, Northen A, Iams JD, Varner MW, Caritis SN, et al. Does progesterone treatment influence risk factors for recurrent preterm delivery? Obstet Gynecol 2005;106:557-661.